BGC 201259

Drug Profile

BGC 201259

Alternative Names: BGC 20-1259; RS 1259

Latest Information Update: 30 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BTG
  • Developer BTG; SAFC Pharma
  • Class Antidementias
  • Mechanism of Action Acetylcholinesterase inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 02 Apr 2009 Discontinued - Phase-I for Alzheimer's disease in Sweden (PO)
  • 02 Apr 2009 Discontinued - Phase-I for Alzheimer's disease in United Kingdom (PO)
  • 30 May 2007 Interim results from a multiple-dose phase I trial in elderly and young volunteers added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top